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Subthalamic or pallidal Deep Brain Stimulation (DBS) are effective treatments for selected 
Parkinson disease (PD) patients.  The effectiveness of subthalamic nucleus (STN) or pallidal DBS 
led logically to efforts to employ DBS in other brain regions to treat aspects of PD lacking 
adequate medical treatments.  Gait and balance deficits unresponsive to dopamine replacement 
therapy are major problems in more advanced PD patients.  The absence of satisfactory medical 
treatments for these problems led to human clinical experiments deploying DBS in the region of 
the pedunculopontine nucleus (PPN) with the goal of alleviating crippling gait and balance 
problems.  The fundamental rationale was that low frequency DBS in the PPN would increase the 
activity of a critical group of PPN neurons.  The clinical experience with PPN DBS was reviewed 
recently1.  In this Viewpoint, we discuss the scientific rationale for PPN DBS and argue that our 
present understanding of the PPN, surrounding regions, and their potential roles in locomotion 
does not provide a good scientific rationale for conventional PPN DBS in PD.  
Original Rationale for PPN DBS 
The origins of the scientific rationale for PPN DBS lies in the 1960’s when investigators in the 
Soviet Union discovered that the region of the mesopontine junction is important in controlling 
locomotion and posture. These investigators found that low intensity electrical stimulation in this 
region induced locomotion in decerebrate cats.2 This electrophysiologically defined region was 
called the Mesencephalic Locomotor Region (MLR).  Subsequent work by Garcia-Rill and 
colleagues suggested that the MLR is centered around the PPN, which is populated by cholinergic 
neurons.3,4 Garcia-Rill and colleagues suggested a model in which MLR-PPN neurons projected to 
a region of the ventromedial medulla (VMM) connected to spinal central pattern generators 
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responsible for locomotion.4 Because cholinergic neurons were a prominent part of the PPN, it 
was widely inferred that they were critical mediators of forebrain inputs regulating locomotion, 
though retrograde tracing data from Garcia-Rill and colleagues strongly implicated non-
cholinergic PPN neurons as the major source of PPN to VMM projections.5  
 
The PPN is a heterogeneous region composed of cholinergic, glutamatergic, GABAergic, and 
probably glycinergic neurons.6,7,8 These different neuron types are not distributed uniformly 
within the PPN. Cholinergic neurons are denser in the caudal than in the rostral portion of the 
PPN, glutamatergic neuron density increases along the rostral to caudal axis, while the GABAergic 
neurons show the opposite pattern.6,8 The connectome of these populations is heterogeneous. 
Oakman and coworkers9, for example, found that substantia nigra pars compacta (SNc) neurons 
receive cholinergic innervation mainly from the rostroventral and medial PPN, while ventral 
tegmental area (VTA) neurons receive cholinergic inputs principally from caudal PPN. The 
cytological and connectional heterogeneity of the PPN is in marked contrast to relatively 
homogeneous STN and GPi. This has potential implications for PPN DBS as a variation in DBS 
electrode position is likely to modulate different circuitry with differing effects on motor 
behavior.  
 
Several observations subsequently suggested that PPN cholinergic neurons were involved in gait 
and balance problems in PD and related disorders. Hirsch et al. described loss of cholinergic PPN 
neurons in PD and Progressive Supranuclear Palsy.10 The magnitude of cholinergic PPN neuron 
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loss was described as greater in PD subjects with a history of falls, consistent with a critical role 
for cholinergic PPN neurons in gait and balance control.11 Positron emission tomography imaging 
studies of cholinergic terminal integrity performed by some of us (NIB, MM, RLA) supported this 
inference.12,13,14 Subsequent work, however (see below), showed that there also is loss (albeit not as 
great) of other PPN neuronal populations in PD patients. 
 
Karachi et al. moved beyond correlative studies with experiments in non-human primates to 
assess whether loss of PPN cholinergic neurons could be causally linked to gait and posture 
deficits. First, they showed that lesioning cholinergic PPN neurons caused gait, balance, and 
posture deficits. Second, they showed that with MPTP lesions, loss of PPN cholinergic neurons 
exacerbated dopamine insensitive gait, balance, and posture deficits 11,15. More recently, 
pharmacogenetic stimulation of PPN cholinergic neurons was reported to reverse gait and 
postural abnormalities in a rat toxin PD model.16  
 
In addition, some studies suggested the emergence of pathophysiological PPN activity in rodent 
PD toxin models.17,18,19 Breit et al. described increased activity and bursting of PPN neurons after 
6-OHDA lesions. Although it was unclear which PPN neuron subpop0ulations was contributing 
to the pathophysiology, it established a parallel with the pathophysiology observed in STN of PD 
patients and the hypothesis that DBS might ameliorate symptoms. Breit et al. also described 
relative normalization of PPN neuron activity in animals with joint 6-OHDA SNc lesions and 
ibotenic acid STN lesions.18 The PPN receives a number of afferent projections from the basal 
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ganglia,6,7 and it is plausible that basal ganglia dysfunction would result in PPN-MLR dysfunction, 
providing an additional rationale for DBS targeting of the PPN in PD. 
 
Recent Studies Contradicting the Original Rationale 
Results of other experiments, however, contradict the idea that cholinergic PPN neurons are 
critical for gait. Neither indiscriminate excitotoxic lesions of PPN neurons nor selective lesions of 
cholinergic PPN neurons produced marked abnormalities in gait in rodents.  Selective lesions of 
PPN cholinergic neurons did not worsen gait impairments resulting from basal forebrain 
cholinergic and striatal dopamine lesions.20,21. 
 
In part, discrepant results may be a consequence of the poorly defined anatomy of the 
operationally-defined MLR. As mentioned above, the MLR was defined on the basis of the 
motoric response to electrical stimulation – an approach that alone cannot be used to precisely 
define the somatodendritic location of the obligate neurons. Work by Takakusaki in decerebrate 
cats suggests that the cuneiform nucleus, which is rostral to the PPN, is essential for stimulation-
induced locomotion22. Lu and colleagues’ experiments in rats have implicated a group of neurons 
ventral to the PPN that project directly to the spinal cord pattern generators.23,24  In fact, work 
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Studies using optogenetic methods to selectively activate neuron subpopulations within the MLR 
shed further doubt on the centrality of PPN cholinergic neurons for locomotion and highlight the 
complexity of MLR functional anatomy. Roseberry et al. attempted to stimulate cholinergic 
neurons, GABAergic neurons, and glutamatergic neurons in this region.25 For technical reasons, it 
was difficult to stimulate cholinergic neurons adequately. In resting mice, stimulation of 
glutamatergic neurons elicited locomotion. In locomoting mice, stimulation of glutamatergic PPN 
neurons significantly accelerated locomotion and stimulation of GABAergic PPN neurons slowed 
locomotion.  This work is consistent with a role for the PPN in the MLR but suggest that 
cholinergic PPN neurons are not the critical population for locomotion.  These results are 
consistent with the older Garcia-Rill group model. In older tract-tracing studies, the PPN-VMM 
projection identified as the key descending pathway for gait activation was found to consist 
mainly of non-cholinergic neurons. Also consistent with the MLR to VMM model, Capelli et al. 
recently described caudal brainstem circuits controlling locomotor velocity.26 This group traced 
MLR efferents to the caudal medulla and found that they originated in both PPN and cuneiform 
nuclei glutamatergic neurons. Caggiano et al. describe both PPN and cuneiform nucleus 
glutamatergic neurons as important for gait control in mice with complex interactions (including 
direct interconnections) between these two nuclei influencing gait speed and gait modes.27 
 
While the original conception of the role of cholinergic PPN neurons focused on regulation of 
brainstem control of locomotion, these neurons have a major rostral projection to the thalamus, 
suggesting a role in modulation of sensory information.6,7  This concept is supported by research 
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in PD subjects indicating a role for these projections in sensory integration to maintain normal 
posture and detection of salient external cues.28,29   
 
PPN glutamatergic neurons also project rostrally. A recent study demonstrated that PPN 
glutamatergic neurons robustly activate SNc dopaminergic neurons, creating yet another way in 
which these neurons might initiate movement.30  By comparison, optogenetic activation of PPN 
cholinergic neurons evokes much smaller responses that are weakly linked to changes in SNc DA 
neuron spiking.31 
 
Lessons from Human Studies 
These results may explain data from some human PPN DBS studies. Two studies report significant 
improvement in gait parameters with PPN DBS in the OFF medication state, but not in the ON 
medication state.32,33 It is plausible that in the OFF medication state, PPN activation of 
dopaminergic neurons produces enough incremental striatal dopamine to make a difference in 
locomotion.  In the ON medication state, however, this modest effect may be obscured by the 
effects of dopamine replacement treatment. In contrast, Stefani and coworkers found that PPN 
DBS stimulation improved gait and posture both in OFF and ON states.34  Further clouding 
interpretation of the clinical outcome data, some PD subjects receiving PPN DBS also underwent 
DBS at conventional targets such as the STN.1  In their recent review, Thevathasan et al. conclude 
that despite the variation in outcomes, when properly positioned, PPN DBS has the potential to 
reduce falls and improve gait in PD patients.1  Thevathasan et al. are appropriately cautious about 
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the existing clinical outcome data and stress that the effect of PPN DBS on the quality of life of PD 
patients remains unproven.1  Efforts at meta-analysis of individual subject data support these 
conclusions.35-37   
 
In spite of some beneficial outcomes in PD patients, the uncertainties surrounding the nature of 
the MLR and the neuronal heterogeneity of the mesopontine region pose significant theoretical 
obstacles to the use of PPN DBS.  Is the PPN the appropriate target? Given the small sizes of the 
involved nuclei and their considerable heterogeneity, the electric fields generated by standard 
DBS electrodes are likely to modulate the activity of multiple nuclei at the mesopontine junction.3  
In their pioneering studies of rostral human brainstem cholinergic neurons, Mesulam et al. 
emphasize that the distribution of mesopontine cholinergic neurons does not follow clear nuclear 
boundaries and that their dendrites interpenetrate a number of surrounding structures.38  This is 
likely true for other PPN neuronal populations as well. As shown by the optogenetic experiments, 
there is considerable functional heterogeneity within this region. The mesopontine region is 
characterized also by the presence of a number of important white matter tracts, increasing the 
risk of significant side effects of stimulation. The challenges of developing accurate stereotaxic 
targeting algorithms and correlating electrode placement, clinical outcomes, and underlying 
anatomy in the rostral brainstem underscores these concerns.39  Even if DBS electrode actions 
could be restricted to one of these nuclei, different and likely contradictory effects will result from 
indiscriminate effects of conventional DBS.  Consistent with this concern, rats with combined 
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toxin lesions of the substantia nigra and PPN were reported to exhibit worsening gait 
performance upon receiving a PPN DBS analogue.20 
 
In addition, there is conflicting information about the effects of dopamine depletion on PPN 
neuronal activity. In non-human primates and in PD patients, data suggest that the PPN activity 
is suppressed in PD; pharmacological disinhibition improves motor behavior in parkinsonian 
MPTP-lesioned primates.40  In contrast, rodent studies suggest either PPN activity is elevated18,41,42, 
suppressed41,43, or not changed45,46 after dopamine depletion. A recent, small non-human primate 
study did not find a change in PPN activity in MPTP lesioned non-human primates.47  These 
discrepancies have yet to be resolved but are likely to stem from the heterogeneity in cell types 
and circuit complexity. 
 
Another issue is that many PPN neurons degenerate in PD.  This includes not only cholinergic 
PPN neurons, but also GABAergic and glycinergic neurons.48 How this pathology affects the 
response of neurons to electrical stimulation is unclear. If the goal is to boost the activity of PPN 
neurons that are compromised, then low frequency stimulation, near the normal autonomous 
rate of cholinergic PPN neurons, should be more effective than higher frequency stimulation 
which is likely to drive neurons into depolarization block. Indeed, low frequency – but not high 
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In summary, what we have learned about the PPN and MLR over the past few years undermines 
the simplistic model that underpins the rationale for PPN DBS.  Our understanding of the 
relevant circuitry remains rudimentary. Further, much of what we know about these circuits is 
based on studies in rodents and felines.  While it is likely that critical features of posture and 
locomotion control are phylogenetically conserved, additional non-human primate experiments 
are needed. Even if we understood the relevant motor circuits in detail, the small sizes of these 
structures, and the considerable heterogeneity of neurons within the PPN and surrounding 
structures, indicates that conventional DBS is too blunt an instrument to selectively target the 
relevant neurons. Finally, manipulating sick neurons adds an additional element of uncertainty. 
In the context of these facts, it is not surprising that the clinical results of PPN DBS are largely 
unimpressive.1 Technical refinements in conventional DBS targeting or technology are unlikely to 
overcome these obstacles. 
 
While basic research revealed significant obstacles to manipulating mesopontine neuronal 
populations, it also indicates circuits in this region are important in gait and balance, and likely 
relevant to PD. It is plausible that cell type specific manipulations in this region with optogenetic 
or chemogenetic methods might be useful.50  That said, deploying these technologies in well-
designed clinical experiments face a number of hurdles, not the least of which is a much firmer 
grasp of the neural circuitry controlling gait and posture is required.   We need also as well to 
know how this circuitry is disrupted in PD.51  At this point in time, human experimentation with 
PPN DBS should be reconsidered.  Efforts should focus on sorting out precisely how the 
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PPN/MLR and their afferent and efferent connections work, on what dysfunctions are 
characteristic of PD, and on developing the technologies needed to rectify these dysfunctions in 
PD patients.  
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